Raybow PharmaScience is a CDMO for Small Molecules with production and R&D facilities located in China and the United States. Raybow has 48+ years experience in chemistry and is focused on sustainable manufacturing of drug substance.

Raybow has 2000+ employees, 450 of which are chemists. We have modern R&D facilities in Suzhou, Hangzhou and Linhai China as well as Brevard, USA.  We manufacture product from gram scale all the way up to multi-tonne.

Our R&D team has resourceful multi-field experienced and international personnel, over 300 people in total, who provide our customers with complete solutions for CDMO projects. The Raybow PharmaScience team is committed to the research and development of new pharmaceutical technology, especially in the area of flow chemistry, high-end fluorine chemistry, asymmetric chiral synthesis, glycosides and biological enzyme technology.

In 2019 a 10,000 square meter PR&D lab was opened in Hangzhou, China. Raybow acquired a lab and manufacturing site in Brevard, NC in the United States and a modern manufacturing site in Suzhou, China. In March of 2020 Raybow added a modern 10,000 square meter PR&D lab to its Linhai site. The company has passed official GMP audits from the USFDA, CFDA and EMEA member countries in recent years. Raybow PharmaScience has applied the concept of green chemical production and manufacturing. Both the Suzhou and Linhai sites have advanced environmental protection & treatment systems, featuring solutions for the company’s waste treatment, and technology for implementing green production and recirculation

Raybow is headquartered in a pharmaceutical production zone in Linhai, Taizhou city of Zhejiang Province and covers an area of 120,000 square meters.